Semaglutide starts GLP-1 receptors in the hypothalamus to reduce appetite and food cravings, enhances insulin secretion while suppressing glucagon, slows gastric emptying to prolong satiety, and may increase energy output
Recommendations have shifted from routine medication cessation to continuation with individualised risk assessment [9, 10]
Clinical oversight remains essential
With steady meal timing, targeted resistance work, weekly tracking, and ongoing behavioral support, you preserve muscle, blunt cravings, and catch small slips before they grow
Although Tirzepatide is primarily used to treat type 2 diabetes, it is gaining popularity as a weight loss treatment
This condition can restrict blood flow and lead to serious health problems, including heart attacks and strokes